1 Secondary
end points included 3-component MACE (myocardial infarction,
2 Secondary
end points included 5-year BPFS, overall BPFS, local recurren
3 Each of these
end points included a prespecified target threshold ranging f
4 Secondary
end points included all-cause death, stent thrombosis, myocar
5 Secondary
end points included all-cause mortality and all major vascula
6 Secondary
end points included angiographic and safety outcomes.
7 Secondary
end points included any infection, hospitalization for infect
8 Secondary
end points included bleeding complications and new infections
9 Other secondary
end points included cartilage thickness on quantitative MRI a
10 End points included change from baseline to week 16 in percen
11 Coprimary
end points included change from baseline to week 24 in Nasal
12 Secondary
end points included change from baseline to week 24 in Sino-N
13 Study
end points included changes in markers of systemic inflammati
14 Secondary
end points included death and appropriate shocks.
15 Secondary
end points included disability worsening confirmed at 3 month
16 The secondary
end points included drowsiness, unpleasant taste, and stingin
17 onse rate (ORR) at 24 weeks (ORR(Wk24)); secondary efficacy
end points included duration of response (DOR), progression-f
18 Secondary
end points included duration of response, progression-free su
19 Functional phenotypic
end points included effects on beating parameters and intrace
20 The secondary
end points included freedom from symptomatic arrhythmia, the
21 Secondary
end points included global cure (GC; CCR without CDI recurren
22 Additional
end points included gluten-specific cluster of differentiatio
23 Secondary and additional
end points included insulin use, the glycated hemoglobin leve
24 End points included LC50 values, and sublethal effects on gro
25 Key secondary
end points included major response rate (MRR), progression-fr
26 Other effectiveness
end points included mean IOP and number of medications at 12
27 Secondary
end points included noninferiority with respect to the primar
28 Key secondary
end points included overall (OS) and progression-free surviva
29 Secondary
end points included overall survival (OS), intracranial progr
30 ry end point was progression-free survival (PFS); secondary
end points included overall survival (OS), response rate, and
31 Secondary
end points included overall survival and safety.
32 Secondary
end points included platelet reactivity and ischemic outcomes
33 Secondary
end points included predisposing factors for treatment respon
34 Secondary
end points included procedural complications within 30 days a
35 centrally assessed objective response rate (ORR); secondary
end points included progression-free survival (PFS), 6-month
36 primary end point was overall survival (OS), and secondary
end points included progression-free survival (PFS), objectiv
37 Secondary
end points included progression-free survival (PFS), toxicity
38 Other efficacy
end points included reductions in the transfusion burden duri
39 The primary end point was pCR, and secondary
end points included RFS, OS, and gene expression analyses.
40 Clinical
end points included safety and clinical remission (modified M
41 Microbiome
end points included SER-287 engraftment (dose species detecte
42 Secondary
end points included survival at 90 days with good cerebral pe
43 Secondary
end points included the change from baseline in 6-minute walk
44 Prespecified exploratory
end points included the concentration of mutant huntingtin in
45 Secondary
end points included the duration of response, progression-fre
46 Secondary
end points included the incidence of culprit vessels with acu
47 Key
end points included the time-weighted average change in viral
48 Secondary
end points included toxicity, compliance, and surgical morbid
49 point was sustained virologic response (SVR), and secondary
end points included uptake of and retention in OAT, change in
50 Primary
end points included VTE recurrence, bleeding events, and mort